Scotia Capital Inc. Buys 66,792 Shares of Haleon plc (NYSE:HLN)

Scotia Capital Inc. raised its stake in Haleon plc (NYSE:HLN) by 567.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 78,563 shares of the company’s stock after purchasing an additional 66,792 shares during the quarter. Scotia Capital Inc.’s holdings in Haleon were worth $750,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in HLN. Wellington Management Group LLP raised its holdings in Haleon by 67.5% during the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock valued at $146,232,000 after buying an additional 6,175,835 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Haleon during the fourth quarter valued at about $42,193,000. FMR LLC boosted its holdings in shares of Haleon by 3.7% during the fourth quarter. FMR LLC now owns 108,827,814 shares of the company’s stock worth $1,038,217,000 after purchasing an additional 3,909,545 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Haleon in the fourth quarter worth about $39,628,000. Finally, JPMorgan Chase & Co. increased its holdings in Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after purchasing an additional 1,026,939 shares during the period. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Up 0.7 %

NYSE:HLN opened at $10.13 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The firm’s 50-day moving average price is $10.05 and its 200-day moving average price is $9.81. The company has a market capitalization of $45.76 billion, a PE ratio of 29.79, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a 1-year low of $8.03 and a 1-year high of $10.80.

Haleon (NYSE:HLN) last announced its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The business had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. On average, equities analysts predict that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The business also recently disclosed a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be paid a dividend of $0.1166 per share. This is a boost from Haleon’s previous — dividend of $0.05. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. Haleon’s payout ratio is presently 58.97%.

Wall Street Analysts Forecast Growth

HLN has been the topic of a number of recent analyst reports. Hsbc Global Res lowered Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Finally, HSBC reissued a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Six investment analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.